Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics
- PMID: 8220911
- PMCID: PMC2175972
- DOI: 10.1111/j.1476-5381.1993.tb13836.x
Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics
Abstract
1. To explain the large differences in (the stereoselectivity of) the clearances of the enantiomers of warfarin and acenocoumarol (4'-nitrowarfarin) their human liver microsomal metabolism has been studied and enzyme kinetic parameters determined. The effects of cimetidine, propafenone, sulphaphenazole, and omeprazole on their metabolism has been investigated. 2. The 4-hydroxycoumarins follow similar metabolic routes and are mainly hydroxylated at the 6- and 7-position (accounting for 63 to 99% of the metabolic clearances). 3. Due to the lower Km values of R- and S-acenocoumarol and higher Vmax values of S-acenocoumarol, the overall metabolic clearances of R/S acenocoumarol exceed those of R/S warfarin 6 and 66 times respectively. 4. The metabolism of both compounds is stereoselective for the S-enantiomers, which is 10 times more pronounced in the case of acenocoumarol. 5. Except for the 7-hydroxylation of the R-enantiomers (r = 0.90; P < 0.025), the 6- and 7-hydroxylation rates of R/S warfarin do not correlate with those of R/S acenocoumarol. 6. Sulphaphenazole competitively inhibits the 7- and in some samples partly (up to 50%) the 6-hydroxylation of S-warfarin as well as the 7-hydroxylation of R- and S-acenocoumarol and the 6-hydroxylation of S-acenocoumarol (Kis ranging from 0.5-1.3 microM). 7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner. 8. Differences in the partial (up to 40%) inhibition of the metabolism of the enantiomers of the 4-hydroxycoumarins were also observed for the relatively weak inhibitors, propafenone and cimetidine.9. The results suggest that the coumarin ring hydroxylations of both compounds are catalysed by different combinations of P450 isozymes. The 7-hydroxylation of R/S acenocoumarol and the 6-hydroxylation of S-acenocoumarol are at least partly conducted by (a) P450 isozyme(s) of the 2C subfamily different from P450 2C9 (the main S-warfarin 7- and 6-hydroxylase).
Similar articles
-
Comparison of the rat liver microsomal metabolism of the enantiomers of warfarin and 4'-nitrowarfarin (acenocoumarol).Xenobiotica. 1991 Mar;21(3):295-307. doi: 10.3109/00498259109039470. Xenobiotica. 1991. PMID: 1862655
-
Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.Drug Metab Dispos. 2000 Nov;28(11):1284-90. Drug Metab Dispos. 2000. PMID: 11038154
-
Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes.Curr Drug Metab. 2005 Oct;6(5):399-411. doi: 10.2174/138920005774330620. Curr Drug Metab. 2005. PMID: 16248835
-
Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.Clin Pharmacokinet. 2005;44(12):1227-46. doi: 10.2165/00003088-200544120-00003. Clin Pharmacokinet. 2005. PMID: 16372822 Review.
-
Human P450 metabolism of warfarin.Pharmacol Ther. 1997;73(1):67-74. doi: 10.1016/s0163-7258(96)00140-4. Pharmacol Ther. 1997. PMID: 9014207 Review.
Cited by
-
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.Clin Pharmacokinet. 1997 Mar;32(3):210-58. doi: 10.2165/00003088-199732030-00004. Clin Pharmacokinet. 1997. PMID: 9084960 Review.
-
Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.Clin Pharmacokinet. 2000 Feb;38(2):111-80. doi: 10.2165/00003088-200038020-00002. Clin Pharmacokinet. 2000. PMID: 10709776 Review.
-
Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.Invest New Drugs. 2004 Apr;22(2):151-8. doi: 10.1023/B:DRUG.0000011791.75522.de. Invest New Drugs. 2004. PMID: 14739663
-
Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.Pharm Res. 2009 Apr;26(4):822-35. doi: 10.1007/s11095-008-9781-2. Epub 2008 Dec 12. Pharm Res. 2009. PMID: 19082874
-
A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.Clin Pharmacokinet. 2012 Jan 1;51(1):41-53. doi: 10.2165/11595560-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22149257 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases